69 completed, 6 terminated, 4 active not recruiting, 4 not yet recruiting. 96 Phase 2, 7 Phase 1, 1 Phase 3.
Follow Plaque Psoriasis: new trials by email Literature Review of Plaque Psoriasis trials Research Report on Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis IRX4204, Placebo - Psoriasis, Plaque Type Psorisis | Phase 2 | Suspended | Io Therapeutics | 20 | 2027-03-01 | 2026-11-12 |
| A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis COL-5671-PRO, Placebo - Plaque Psoriasis | Phase 2 | Not yet recruiting | Coultreon Biopharma | 100 | 2026-10-31 | 2026-11-03 |
| An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis ORKA-002 - Plaque Psoriasis | Phase 2 | Enrolling by invitation | Oruka Therapeutics, Inc. | 160 | 2026-10-26 | 2026-11-12 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis SHR-1139, SHR-1139 and SHR-1139 pleacebo - Plaque Psoriasis | Phase 2 | Not yet recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 50 | 2026-08-01 | 2026-08-11 |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis ORKA-002, Placebo - Plaque Psoriasis | Phase 2 | Active not recruiting | Oruka Therapeutics, Inc. | 160 | 2026-03-19 | 2026-10-16 |
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis ORKA-001 - Plaque Psoriasis | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | 240 | 2026-02-23 | 2026-10-23 |
| Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis ICP-332 Tablets, ICP-332 Placebo Tablets - Plaque Psoriasis | Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 182 | 2025-12-22 | 2026-11-13 |
| Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis ORKA-001, Placebo - Plaque Psoriasis | Phase 2 | Active not recruiting | Oruka Therapeutics, Inc. | 160 | 2025-12-03 | 2026-11-06 |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose） - Plaque Psoriasis | Phase 1 / Phase 2 | Recruiting | Chipscreen Biosciences, Ltd. | 220 | 2025-09-08 | 2026-11-05 |
| A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis HSK47388 - Plaque Psoriasis | Phase 2 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 220 | 2025-09-01 | 2025-09-05 |
| ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis ORKA-001 Induction Dose, Placebo, ORKA-001 Maintenance Dose - Plaque Psoriasis | Phase 2 | Active not recruiting | Oruka Therapeutics, Inc. | 80 | 2025-07-18 | 2026-07-01 |
| A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis LY4100511, Placebo - Plaque Psoriasis | Phase 2 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 222 | 2024-10-25 | 2026-08-18 |
| Treatment of Moderate to Severe Plaque Psoriasis TQH3906 capsules, Placebo of TQH3906 capsules - Plaque Psoriasis | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 209 | 2024-08-27 | 2026-01-30 |
| A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis ZL-1102 1% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel QD for 16 weeks - Plaque Psoriasis | Phase 2 | Terminated | Zai Lab (Hong Kong), Ltd. | 65 | 2024-05-22 | 2026-08-10 |
| A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis AC-201, Placebo - Plaque Psoriasis | Phase 2 | Completed | Accro Bioscience (Suzhou) Limited | 145 | 2024-04-23 | 2025-05-22 |
| Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis D-2570, Placebo - Plaque Psoriasis | Phase 2 | Completed | InventisBio Co., Ltd | 161 | 2024-01-31 | 2025-12-09 |
| A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis LY3972406, Placebo - Plaque Psoriasis | Phase 2 | Completed | Eli Lilly and Company | 33 | 2023-12-06 | 2025-10-15 |
| Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis AX-158, Placebo - Psoriasis, Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Artax Biopharma Inc | 31 | 2023-11-30 | 2025-10-03 |
| Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis Jiuweihuaban Pill placebo, low dose Jiuweihuaban Pill, high dose Jiuweihuaban Pill - Plaque Psoriasis | Phase 2 | Unknown | Tasly Pharmaceutical Group Co., Ltd | 180 | 2023-11-23 | 2024-09-03 |
Showing 20 of 96. Sign in to see all of them.
Psoriasis (25) · Skin Diseases (5) · Plaque, Amyloid (4) · Dermatitis, Atopic (2) · Lymphoma, Follicular (2) · Pruritus (2) · Autoimmune Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Chronic Urticaria (1) · Eczema (1) · Erythema (1) · Lichen Planus (1) · Neurodermatitis (1) · Skin Diseases, Papulosquamous (1)
Skin and Connective Tissue Diseases (29) · Skin Diseases, Papulosquamous (26) · Skin Diseases (24) · Immune System Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Pathological Conditions, Anatomical (4) · Dermatitis (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Skin Diseases, Eczematous (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2)
Exercise (5) · Roflumilast (3) · CF101 (2) · Mometasone Furoate (2) · N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (2) · Nortriptyline (2) · Salicylic Acid (2) · calcipotriene (2) · halobetasol (2) · ADX-629 (1) · AGN 194204 (1) · Coal Tar (1) · INCB039110 (1) · IRX4204 (1) · Population Groups (1)
Therapeutics, Inc. (6) · Arcutis Biotherapeutics, Inc. (5) · Oruka Therapeutics, Inc. (5) · Pfizer (4) · Janssen Research & Development, LLC (3) · Sun Pharmaceutical Industries, Inc. (3) · Akeso (2) · Akros Pharma Inc. (2) · Alumis Inc (2) · AmDerma (2) · Can-Fite BioPharma (2) · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (2) · Eli Lilly and Company (2) · Maruho Co., Ltd. (2) · Santalis Pharmaceuticals, Inc. (2)
United States (58) · Canada (30) · Germany (15) · China (12) · Poland (10) · United Kingdom (7) · Hungary (5) · Japan (5) · Spain (5) · Australia (4) · France (4) · Bulgaria (3) · Czechia (3) · Dominican Republic (3) · Ukraine (3)
David Berk, MD (5) · Syd Dromgoole, PhD (3) · Hongzhong Jin, MD (2) · Albrecht Georg Schmidt, MD (1) · Alexandre Frederico, Doctor (1) · Amir Larian, MD (1) · Anke Gauliard, MD (1) · Benjamin Ehst, MD PhD (1) · Binu J Alexander (1)
PMID 40862624, PMID 41424381, PMID 20926833, PMID 21504485, PMID 26390837, PMID 27059729, PMID 27876460, PMID 29657667, PMID 30207587, PMID 32228720, PMID 32668113, PMID 32816215, PMID 34713415, PMID 35061234, PMID 35342978, PMID 36370336, PMID 38117526, PMID 38324484, PMID 38813388, PMID 38896380, PMID 39971605, PMID 40135074, PMID 40659116, PMID 40967307, PMID 41061968
2016 (1), 2017 (1), 2023 (1)